The study of >1000 patients reached its primary endpoint of recognizing clinical heart failure with smartphone-based technology. Comprehensive results of the study will be published later in 2022.

CardioSignal, a health technology company developing motion sensor technology to improve heart disease detection, was announced a winner in the Innovation Pitch Challenge by American College of Cardiology's Annual Scientific Session & Expo 2022 in Washington D.C. on April 3, 2022. The Pitch Challenge was organized in partnership with the National Heart Lung and Blood Institute (NHLBI).

To enable the early detection of atrial fibrillation and subsequent intervention, Mehiläinen and CardioSignal are collaborating to build a digital health approach that includes offering home monitoring to at-risk individuals in Finland. Early detection of atrial fibrillation has the potential to significantly reduce future hospitalizations from heart failure or stroke.

The collaboration includes making easy-to-use, at-home monitoring of atrial fibrillation available for at-risk individuals in France through a network of 1,000 cardiologists. The initiative aims to reach 5,000 individuals to prevent adverse health outcomes caused by undiagnosed atrial fibrillation.

With this collaboration, CardioSignal’s motion sensor technology for heart disease detection is made available for healthcare professionals by combining it with Roche’s blood glucometer.

With a large population with over half a billion smartphone users and growing demand for at-home solutions in heart health monitoring, India is the next natural step in CardioSignal’s global expansion.